Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 0.90 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.90 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.64 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.61 |
| ▸ | QPCT | Q16769 | 1/20 | 0.61 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.61 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77025 | 0.95 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| Hydrochloric Acid SCHEMBL30946847 | 0.93 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL2529997 | 0.91 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL1024261 | 0.85 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL2033990 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL2728400 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.83 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL11957614 | 0.81 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL7284368 | 0.80 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 | |
| SCHEMBL6057476 | 0.80 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP17A1CYP19A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | CYP11B1 444/4885CYP11B2 364/4885CYP17A1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.